Gritstone Oncology Announces Upcoming Presentation on Novel Shared Neoantigens Included within “Off-The-Shelf” SLATE Immunotherapy at SITC 2019 Annual Meeting
October 07, 2019 08:00 ET
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
Tempest Therapeutics Announces Multiple Presentations at Upcoming SITC 34th Annual Meeting
October 02, 2019 16:00 ET
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class small molecules...
Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
October 01, 2019 18:01 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2018 Financial Results
November 13, 2018 06:30 ET
|
Jounce Therapeutics, Inc.
- Dose escalation cohorts of JTX-2011 Phase 1/2 ICONIC trial, in combination with ipilimumab and in combination with pembrolizumab, on track - - IND filed and clearance to proceed received for...
Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
November 10, 2018 12:20 ET
|
Jounce Therapeutics, Inc.
- Characterization of emerging ICOS hi CD4 T cells from responding patients provides rationale for JTX-2011 combination therapies - CAMBRIDGE, Mass., Nov. 10, 2018 (GLOBE NEWSWIRE) -- Jounce...
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
November 06, 2018 08:00 ET
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
November 02, 2018 13:48 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
March 19, 2018 16:05 ET
|
aTyr Pharma, Inc.
SAN DIEGO, March 19, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
December 21, 2017 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immuno-modulatory protein therapeutics to treat...
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
November 10, 2017 08:00 ET
|
VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...